M. Furukawa

发表

Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity.

S. Nonen, Y. Fujio, J. Azuma, 2013, Clinical lung cancer.

Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism.

S. Nonen, I. Kawase, S. Goya, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The extracellular domain of p185(c-neu) induces density-dependent inhibition of cell growth in malignant mesothelioma cells and reduces growth of mesothelioma in vivo.

I. Kawase, M. Greene, T. Kijima, 2006, DNA and cell biology.

A phase I/II study comparing regimen schedules of gemcitabine and docetaxel in Japanese patients with stage IIIB/IV non-small cell lung cancer.

T. Mukohara, M. Fukuoka, S. Kudoh, 2005, Japanese journal of clinical oncology.

A 78-Year-Old Man With Repeated Dyspnea and Neutrophilia in Peripheral Blood and BAL.

M. Matsushita, M. Furukawa, H. Tagawa, 2020, Chest.

The gefitinib-sensitizing mutant epidermal growth factor receptor enables transformation of a mouse fibroblast cell line.

I. Kawase, M. Greene, T. Kijima, 2006, DNA and cell biology.

Preliminary experience with a modified premedication protocol that included intravenous diphenhydramine and calcium bromide for the prophylaxis of paclitaxel-related hypersensitivity reactions

Yukiko Nakamura, I. Kawase, T. Nitta, 2007, International Journal of Clinical Oncology.

Overexpression of PIAS 3 Suppresses Cell Growth and Restores the Drug Sensitivity of Human Lung Cancer Cells in Association with PI 3K / Akt Inactivation

I. Kawase, T. Kijima, T. Naka, 2014 .

Overexpression of PIAS3 suppresses cell growth and restores the drug sensitivity of human lung cancer cells in association with PI3-K/Akt inactivation.

I. Kawase, T. Kijima, T. Naka, 2006, Neoplasia.

Phase I study of weekly cisplatin, vinorelbine, and concurrent thoracic radiation therapy in patients with locally advanced non-small-cell lung cancer

I. Kawase, T. Tada, K. Minakuchi, 2006, International Journal of Clinical Oncology.

Gefitinib-sensitive EGFR lacking residues 746-750 exhibits hypophosphorylation at tyrosine residue 1045, hypoubiquitination, and impaired endocytosis.

I. Kawase, S. Goya, M. Greene, 2007, DNA and cell biology.